menu
    • menu
    [{"orgOrder":0,"company":"CEPI","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"VBI-2905","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CEPI","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"SK Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"GBP510","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"CEPI","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"7","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CEPI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"SK Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"GBP510","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"CEPI","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"7","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"IAVI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"rVSV\u2206G-LASV-GPC","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CEPI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"Gritstone bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Self-amplifying mRNA Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CEPI","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"Clover Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"SCB-2019","moa":"SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CEPI","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.40000000000000002,"dosageForm":"Intramuscular Injection","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"10","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"Gritstone bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"SAM Covid-19 vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CEPI","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Dosage Strength\/Form","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"Affinivax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Covid-19 Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"CEPI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"2","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"Vaxxinity","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"UB-612","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CEPI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"10","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"Affinivax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"24-Valent Pneumococcal Vaccine","moa":"B-Cell antibody","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CEPI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"Intravacc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Avacc 101","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CEPI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"SK Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA-based Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CEPI","amount2":0.14000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"1","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"VBI-2900","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"CEPI","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"3","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"aVaxziPen","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"Protein-based Vaccine","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"CEPI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"3","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"BNT166","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CEPI","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.089999999999999997,"dosageForm":"Injectable\/Injection","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"mRNA Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"CEPI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"3","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"VTP-500","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CEPI","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"8","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"Live Modified Vaccinia Virus Ankara","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CEPI","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"BNT165e","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"CEPI","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"7","companyTruncated":"CEPI \/ CEPI"},{"orgOrder":0,"company":"CEPI","sponsor":"Valneva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Chikungunya Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CEPI","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CEPI \/ CEPI","highestDevelopmentStatusID":"14","companyTruncated":"CEPI \/ CEPI"}]

    Find Clinical Drug Pipeline Developments & Deals by CEPI

    Menu

    CEPI

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chikungunya Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Valneva

                            Deal Size : $41.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CEPI Expands Partnership with Valneva with $41.3M Grant for Chikungunya Vaccine

                            Details : The funding will support trials of Ixchiq Chikungunya Vaccine in vulnerable groups, such as children and pregnant women. It is already approved for use in adults 18 years of age and older.

                            Brand Name : Ixchiq

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            July 22, 2024

                            Lead Product(s) : Chikungunya Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Valneva

                            Deal Size : $41.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Live Modified Vaccinia Virus Ankara

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Bavarian Nordic

                            Deal Size : $6.5 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa

                            Details : The partnership aims to advance the development of Bavarian Nordic’s mpox vaccine, MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic, a non-replicating vaccine, in children in Africa.

                            Brand Name : MVA-BN

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 30, 2024

                            Lead Product(s) : Live Modified Vaccinia Virus Ankara

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Bavarian Nordic

                            Deal Size : $6.5 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNT165e

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Recipient : BioNTech

                            Deal Size : $145.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            BioNTech and CEPI Expand Partnership to Strengthen Africa's mRNA Vaccine Ecosystem

                            Details : BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines like BNT165 against malaria, mpox and tuberculosis in Africa.

                            Brand Name : BNT165e

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 29, 2024

                            Lead Product(s) : BNT165e

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Recipient : BioNTech

                            Deal Size : $145.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VTP-500

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Barinthus Biotherapeutics

                            Deal Size : $34.8 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            New Partnership Aims to Advance Vaccine Against MERS Coronavirus

                            Details : The partnership aims to fast-track the development of a vaccine candidate known as VTP-500 for the prevention of Middle East Respiratory Syndrome, the often fatal disease caused by the MERS coronavirus.

                            Brand Name : VTP-500

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 21, 2023

                            Lead Product(s) : VTP-500

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Barinthus Biotherapeutics

                            Deal Size : $34.8 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery Platform

                            Recipient : Moderna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission

                            Details : New partnership will harness Moderna's mRNA rapid-response platform, clinically validated during the COVID-19, to accelerate epidemic and pandemic vaccine development. First project will enable rapid pre-clinical testing of antigen designs for high-risk ...

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 30, 2023

                            Lead Product(s) : mRNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery Platform

                            Recipient : Moderna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNT166

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : BioNTech

                            Deal Size : $90.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days ...

                            Details : The partnership aims to advance mRNA-based vaccine candidates with the development of BNT166 for the prevention of mpox (formerly monkeypox, caused by a member of the Orthopoxvirus viral family), an infectious disease that can lead to severe, life-threat...

                            Brand Name : BNT166

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 18, 2023

                            Lead Product(s) : BNT166

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : BioNTech

                            Deal Size : $90.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Protein-based Vaccine

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Recipient : aVaxziPen

                            Deal Size : $1.6 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Needle-free Vaccine Delivery Platform Aims To End Frozen Storage Needs And Improve Access

                            Details : The partnership aims to advance the development of two vaccines candidates (one protein and one mRNA-based) using aVaxziPen’s solid dose vaccine-delivery platform, which could help end the need for frozen storage of vaccines, thereby improving equitabl...

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 06, 2023

                            Lead Product(s) : Protein-based Vaccine

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Recipient : aVaxziPen

                            Deal Size : $1.6 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VBI-2900

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery Platform

                            Recipient : VBI Vaccines

                            Deal Size : $33.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal

                            Details : Application of the funding will be directed into the broader development of the VBI-2900 coronavirus vaccine program to explore the ‘Coronavirus X’ potential of VBI’s technology.

                            Brand Name : VBI-2900

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 07, 2022

                            Lead Product(s) : VBI-2900

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery Platform

                            Recipient : VBI Vaccines

                            Deal Size : $33.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : SK Bioscience

                            Deal Size : $140.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            SK Bioscience and CEPI Sign Agreement to Develop mRNA Vaccines

                            Details : Under the agreement, SK bioscience will receive R&D expenses from CEPI. Initial funding will be made available to support phase 1/2 clinical trials of two mRNA vaccine platform projects.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 25, 2022

                            Lead Product(s) : mRNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : SK Bioscience

                            Deal Size : $140.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed

                            CEPI

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avacc 101

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Intravacc

                            Deal Size : $4.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CEPI Partners With Intravacc To Develop An Intranasal, Broadly Protective Betacoronavirus Vaccine

                            Details : CEPI’s funding will support preclinical development and testing of Intravacc’s subunit vaccine candidate Avacc 101, which is based on its Outer Membrane Vesicle (OMV) platform.

                            Brand Name : Avacc 101

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 06, 2022

                            Lead Product(s) : Avacc 101

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Intravacc

                            Deal Size : $4.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth